tetano
Editor, Senior Moderator
Emerg Infect Dis
. 2021;27(7):1821-1830.
doi: 10.3201/eid2707.210462.
Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2
Bo Shu, Marie K Kirby, William G Davis, Christine Warnes, Jimma Liddell, Ji Liu, Kai-Hui Wu, Norman Hassell, Alvaro J Benitez, Malania M Wilson, Matthew W Keller, Benjamin L Rambo-Martin, Yamundow Camara, Jörn Winter, Rebecca J Kondor, Bin Zhou, Stacey Spies, Laura E Rose, Jonas M Winchell, Brandi M Limbago, David E Wentworth, John R Barnes
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 10[SUP]2.0[/SUP], influenza B virus at 10[SUP]2.2[/SUP], and SARS-CoV-2 at 10[SUP]0.3[/SUP] 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2.
Keywords: 2019 novel coronavirus disease; COVID-19; Flu SC2 Multiplex; SARS-CoV-2; acute respiratory infections; coronavirus disease; coronaviruses; influenza; influenza A; influenza B; multiplex; real-time RT-PCR; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.
. 2021;27(7):1821-1830.
doi: 10.3201/eid2707.210462.
Multiplex Real-Time Reverse Transcription PCR for Influenza A Virus, Influenza B Virus, and Severe Acute Respiratory Syndrome Coronavirus 2
Bo Shu, Marie K Kirby, William G Davis, Christine Warnes, Jimma Liddell, Ji Liu, Kai-Hui Wu, Norman Hassell, Alvaro J Benitez, Malania M Wilson, Matthew W Keller, Benjamin L Rambo-Martin, Yamundow Camara, Jörn Winter, Rebecca J Kondor, Bin Zhou, Stacey Spies, Laura E Rose, Jonas M Winchell, Brandi M Limbago, David E Wentworth, John R Barnes
- PMID: 34152951
- DOI: 10.3201/eid2707.210462
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019, and the outbreak rapidly evolved into the current coronavirus disease pandemic. SARS-CoV-2 is a respiratory virus that causes symptoms similar to those caused by influenza A and B viruses. On July 2, 2020, the US Food and Drug Administration granted emergency use authorization for in vitro diagnostic use of the Influenza SARS-CoV-2 Multiplex Assay. This assay detects influenza A virus at 10[SUP]2.0[/SUP], influenza B virus at 10[SUP]2.2[/SUP], and SARS-CoV-2 at 10[SUP]0.3[/SUP] 50% tissue culture or egg infectious dose, or as few as 5 RNA copies/reaction. The simultaneous detection and differentiation of these 3 major pathogens increases overall testing capacity, conserves resources, identifies co-infections, and enables efficient surveillance of influenza viruses and SARS-CoV-2.
Keywords: 2019 novel coronavirus disease; COVID-19; Flu SC2 Multiplex; SARS-CoV-2; acute respiratory infections; coronavirus disease; coronaviruses; influenza; influenza A; influenza B; multiplex; real-time RT-PCR; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses.